Applied DNA Stock Jumps On New COVID-19 Testing Contract

by Vandana Singh, Benzinga Editor

September 2, 2021 8:37 AM | 1 min read

Applied DNA Sciences Inc's APDN subsidiary Applied DNA Clinical Labs has been awarded a testing contract by Suffolk County Community College.
Also Read: Applied DNA Receives COVID-19 testing contract by the City University of New York
Testing is scheduled to begin in the second half of September 2021. The initial contract term is one year and includes two one-year options for renewal.
The contract contains no minimum testing requirement; it stipulates a fixed monthly fee for sample collection site services and a separate fixed fee per individual COVID-19 test.
Under the Contract, Applied DNA will deploy safeCircle, a pooled COVID-19 testing program.
Price Action: APDN stock is up 3.07% at $6.05 during the premarket session on the last check Thursday.

Posted In: Long Ideas News Health Care Contracts Movers Trading Ideas General Briefs COVID-19 Coronavirus

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.